Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9159886 | 1.00 | IDO1 (0.49) | IDO1HTTALDH1A1KMT2AMEN1 | |
| SCHEMBL9167813 | 1.00 | IDO1 (0.49) | IDO1HTTALDH1A1KMT2AMEN1 | |
| SCHEMBL384148 | 0.88 | IDO1 (0.46) | IDO1CHRNA7 | |
| SCHEMBL9165647 | 0.88 | IDO1 (0.46) | IDO1CHRNA7 | |
| SCHEMBL779498 | 0.81 | IDO1 (0.49) | IDO1HTTALDH1A1KMT2AMEN1 | |
| SCHEMBL9261609 | 0.81 | IDO1 (0.49) | IDO1HTTALDH1A1KMT2AMEN1 | |
| SCHEMBL1942800 | 0.79 | IGF1R (0.36) | IDO1HTTALDH1A1KMT2AMEN1 | |
| SCHEMBL25189588 | 0.76 | IDO1 (0.43) | IDO1HTTALDH1A1KMT2AMEN1 | |
| SCHEMBL9160631 | 0.75 | CHRNB2 (0.44) | KMT2A | |
| SCHEMBL4656200 | 0.75 | CHRNB2 (0.44) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740584-B9 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2010-06-09 | — | — | EP | claimed |
| JP-4361566-B2 | — | — | 2009-11-11 | — | — | JP | claimed |
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | US | claimed |
| EP-2080760-A1 | Fused quinoline derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-07-22 | — | — | EP | claimed |
| EP-1740584-B1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2008-12-03 | — | — | EP | claimed |
| EP-1653960-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1252890-B1 | REMEDIES OR PREVENTIVES FOR DIGESTIVE DISEASES CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVES | ISHIHARA SANGYO KAISHA (JP) | 2008-07-02 | — | — | EP | claimed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | claimed |
| JP-2007534638-A | — | — | 2007-11-29 | — | — | JP | claimed |
| US-20070031415-A1 | Regulation of interaction between rapl and rap1 | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2007-02-08 | — | — | US | claimed |
| EP-1252889-A1 | REMEDIES OR PREVENTIVES FOR PULMONARY INSUFFICIENCY CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVES | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2002-10-30 | — | — | EP | claimed |
| WO-2001047899-A1 | SUBSTITUTED PIPERAZINE DERIVATIVES AS MTP INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-07-05 | — | — | WO | claimed |
| EP-0469887-B1 | Acetamide derivatives | ZENECA LTD (GB) | 1994-12-14 | — | — | EP | claimed |
| US-4898876-A | Benzoylpiperazine esters and a process for their production | KOWA CO., LTD. (JP) | 1990-02-06 | — | — | US | claimed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | claimed |
| US-4267340-A | BACTERICIDES; SYNTHESIS OF PENICILLINS AND CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-12 | — | — | US | claimed |
| US-4092474-A | Cephalosporins having a metaloxy group in 3-substituent | SHIONOGI & CO., LTD. (JA) | 1978-05-30 | — | — | US | claimed |
| US-4091210-A | Preparation of 3-alkyl-3-cephem-4-carboxylic acid compounds from dithio isopropenyl azetidine carboxylic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1978-05-23 | — | — | US | claimed |
| US-4009159-A | PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-02-22 | — | — | US | claimed |
| US-3993646-A | Process for the ring expansion of penicillins to cephalosporin compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-11-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | IDO1 948/4885HTT 3553/4885ALDH1A1 2927/4885 |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TACR2, HRH3, HRH2 | IDO1 905/4885HTT 3444/4885ALDH1A1 2917/4885 |
| US-20070031415-A1 | Regulation of interaction between rapl and rap1 | RAP1A, RAPGEF3, RAPGEF4 | IDO1 3526/4885HTT 4539/4885ALDH1A1 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.